Patritumab deruxtecan or HER3-DXd is a novel antibody-drug conjugate that consists of a HER3 antibody attached to a topoisomerase I inhibitor payload via a cleavable linker. It is currently being studied in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor (TKI) therapy.
Early studies of patritumab deruxtecan have shown promising results, with a response rate of 39% and a median progression-free survival (mPFS) of 8.2 months in patients with EGFR-mutated NSCLC. This makes it a potentially new treatment option for patients who have already received EGFR TKI therapy and have limited options for further treatment.
As with any new treatment, further studies are needed to fully evaluate the safety and efficacy of patritumab deruxtecan in this patient population. However, these early results are encouraging and suggest that this therapy may play an important role in the future management of EGFR-mutated NSCLC.
In summary, patritumab deruxtecan or HER3-DXd is a promising new treatment option for patients with advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR TKI therapy. Further research is needed to fully evaluate its potential, but it is an exciting development to stay tuned for.
